CMS Feb 24, 2022 Medicare Contractor's Final Coverage Decision on NGS Cancer Testing Appeases Industry Stakeholders Premium Feb 17, 2022 Senate Bill Proposes to Expand Medicare Coverage for Hereditary Cancer Testing Jan 31, 2022 CMS No Longer Reimbursing Interpace Bio Thyroid Tests; Firm's Rights Offering Terminated Jan 7, 2022 Banner Year for Blood-Based Cancer Screening in 2021, but Reimbursement and Utility Hurdles Loom Premium Nov 11, 2021 Palmetto Finalizes Medicare Coverage for MRD Cancer Testing Oct 25, 2021 Labs Ask Medicare Contractor to Refine Coverage Policy for 'Comprehensive' NGS Cancer Testing Premium May 28, 2021 Postponed CMS Proposal Would Remove Unspecified Cancer Dx Codes, Impacting Test Access Premium May 17, 2021 Oncologists, Patients Still Face Unpredictable Payor Coverage for Broad Tissue NGS Panels Premium Mar 31, 2021 Biocept Prepares for First FDA Foray With CSF Liquid Biopsy Brain Metastases Assay Premium Mar 5, 2021 MSK Study Finds Survival Gap Between Clinical Trial, Real-World Patients on Approved Cancer Drugs Premium Mar 2, 2021 PreludeDx DCIS Breast Cancer Test Helps Determine Radiation Therapy Benefits, Reduce Overtreatment Premium Jan 20, 2021 CMS Finalizes Blood-Based Colon Cancer Screening NCD with Non-Coverage for Epi ProColon Dec 2, 2020 Diaceutics, Alva10 Gathering Evidence Base for Improving PD-L1 Test Reimbursement Premium Oct 19, 2020 CMS Colon Cancer Screening Memo Bodes Well for Assays in Development; Denies Epi ProColon Sep 14, 2020 COVID-19 Experience Spurs Cancer Research Community to Embrace Telemedicine-Enabled Trials Jul 31, 2020 Medicare to Cover Myriad Genetics' BRACAnalysis for FDA-Approved CDx Indications Jan 27, 2020 CMS to Cover FDA-Approved, -Cleared NGS Germline Tests for Breast, Ovarian Cancer Patients Dec 3, 2019 Palmetto Issues Final LCD for Decipher Biosciences Prostate Cancer Test Oct 30, 2019 CMS Proposes New National Coverage Policy for NGS Germline Testing Aug 26, 2019 Stakeholders Voice Concerns, Push Back on NCD for NGS Cancer Panels Premium Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
